Natco Pharma has invested around $2 million in Cellogen Therapeutics to support development of affordable cell and gene therapies in India. Cellogen is primarily involved in two R&D programs involving cell and gene therapy solutions. Chimeric Antigen Receptor T (CAR T) cell therapy program is at an advanced stage for Cellogen Therapeutics where the T cells of the patients are genetically engineered to identify and kill the cancer cells.
Cellogen Therapeutics has developed bi-specific CARs and also added another costimulatory domain to increase the efficacy and persistence of the CAR in human body as compared to currently available CAR constructs that are mono-specific with one co-stimulatory domain. Both these innovations are aimed at reducing the risk of relapse post CAR T cell therapy which remains a major challenge with existing CAR constructs. Current available products in market cost around $500,000 - 700,000 which Cellogen aims to bring down to $60,000 - 70,000.
Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1751.05 |
Dr. Reddys Lab | 1163.70 |
Cipla | 1515.45 |
Lupin | 1936.75 |
Zydus Lifesciences | 831.40 |
View more.. |